This #worldliverday , help us shape the future of liver care by participating in our #MAFLD #MASH patient survey, as announced in our press release. Share your experiences and help improve treatment and support for all!➡️shorturl.at/AFGJ0 #StepUpForLiverHealth #livertwitter

The #NASH / #MASH community has been waiting a long time for an approved treatment option. Today, it is finally available in the U.S. Learn more here: bit.ly/4arUmPg

We look forward to discussing the latest in #NASH / #MASH research with industry leaders and experts at the CLDFoundation 4th Annual #LiverConnect Conference. We hope to see you there! #CLDF bit.ly/49gCAgl

Today, we've announced NEJM published the primary results of our pivotal Phase 3 MAESTRO-NASH trial. We hope the publication will serve as a catalyst for #NASH research and help advance care for patients with this serious #LiverDisease . bit.ly/3utesJi

Dr. Stephen Harrison and Naim Alkhouri share a fabulous, and energetic update on NASH today. Thank you Madrigal Pharmaceuticals for the leadership, sponsoring this update #TLM23 AASLD.

Stephen Harrison:

- “the #1 killer is cardiovascular disease”
- “fatty liver is the…

Bill Sibold shares his perspective attending his first @AASLDTweets Liver Meeting as Madrigal CEO. Learn more. #TLM23 #LiverTwitter bit.ly/469jcAz

This week, we look forward to presenting new data at the AASLD Liver Meeting. Follow along to learn more about our abstracts. #TLM23 #LiverTwitter bit.ly/3u9QBO6

Meet your body's backstage boss: the liver! Rubbing shoulders with your gallbladder and stomach, this football-sized powerhouse can be found on the upper right side of your body, tucked beneath your ribcage! #get2knowyourliver

Press Release: Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis #LiverTwitter ir.madrigalpharma.com/news-releases/…

Madrigal announced today that Bill Sibold has been appointed Chief Executive Officer, succeeding Dr. Paul Friedman, who will continue to serve on Madrigal’s Board of Directors. Welcome to the team Bill! Read our press release here: ir.madrigalpharma.com/news-releases/…

The Madrigal team is heading to the Paris NASH meeting this week – we hope to see you there! #LiverTwitter

Press release: Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results #LiverTwitter ir.madrigalpharma.com/news-releases/…

Press release: Madrigal Pharmaceuticals Completes Submission of New Drug Application Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis #LiverTwitter ir.madrigalpharma.com/news-releases/…

Press release: Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis #LiverTwitter ir.madrigalpharma.com/news-releases/…

La población Latina en 🇺🇸 está siendo muy altamente afectada por la enfermedad de hígado graso. Escucha más información en este podcast de @EIZol1079➡️shorturl.at/mEX56 #EHGNA #EHNA #livertwitter